Navigation Links
Novartis files application with FDA for Zometa

Novartis Pharmaceuticals has submitted an application to the Food and Drug Administration, seeking marketing authorization for Zometa in the treatment of bone complications associated with a broad range of tumor types. These include prostate and lung cancer, for which no bisphosphonate therapy is currently approved. The spread of cancerous cells from the original tumor to the bone, can lead to serious complications called skeletal related events like fractures, compression of the spinal cord, severe bone pain and hypercalcemia.//

Zometa is a new generation intravenous bisphosphonate that was approved by the FDA just two weeks ago (20 August 2001) for the treatment of hypercalcemia of malignancy (HCM), the most common life-threatening metabolic complication of cancer. To date, Novartis has received marketing clearances for Zometa in the treatment of hypercalcemia of malignancy (HCM) in more than 30 countries.

"Bone complications can be extremely debilitating to cancer patients, and seriously impact their day to day activities. Zometa offers these patients an effective treatment with a convenient 15-minute infusion time. Novartis is pleased to bring forward another drug that will help make a marked difference in the lives of cancer patients and their families" said David Epstein, President, Novartis Oncology.

Three trials have been successfully conducted, evaluating more than 3,000 patients. This is the largest set of clinical trials ever conducted to evaluate the efficacy and tolerability of bisphosphonates in treating bone complications.


'"/>




Page: 1

Related medicine news :

1. Canine Painkiller unveiled by Novartis
2. Glivec the hot cancer drug from Novartis
3. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
4. Novartis MS Drug Shows Promising Results
5. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
6. Drop Patent Petition, Activists Ask Novartis
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
9. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
10. Novartis Drug Diovan Shows Superior Benefits
11. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... lien basis to help personal injury victims find high quality medical care. When the ... Los Angeles area. Fast forward to present day and the now ten-page directory features ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. ... Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at an early ... medicine is about more than making diagnoses and prescribing medicine,” he states. “It is ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... California, will be included in the 2016 “Guide to America’s Top Plastic Surgeons” ... on the amalgamation of their education, experience, and professional associations. , One ...
(Date:12/2/2016)... Delaware (PRWEB) , ... December 02, 2016 , ... ... released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps ... sample entry through labeling, storing, shipping and disposal. The new version is a ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Around the corners of world, cancer ... habitable land present over earth. Cancer has become one ... a life time this is because of the increasing ... Given the steady increase in global cancer incidence with ... healthcare costs of treatment, there is increasing interest in ...
(Date:12/2/2016)... -- The iShares Nasdaq Biotechnology Exchange-Traded Fund has ... early in November. Less political risk has boosted the ... an uptick in M&A activities. Today, Stock-Callers.com takes a ... have fared at the last close: Celldex Therapeutics Inc. ... FOLD ), Navidea Biopharmaceuticals Inc. (NYSE MKT: ...
(Date:11/30/2016)... , Nov. 30, 2016  Millennium Dental Technologies, Inc. announced ... in the Superior Court of the State of ... alleging violation of the California,s Uniform ... unfair and fraudulent business practices which are untrue and misleading, ... This is the second time in three years ...
Breaking Medicine Technology: